What we're reading, September 7, 2016: Allergan vows to limit drug price hikes; Senate votes again to block Zika funding bill; and CMS will institute a new process to screen people signing up for Obamacare coverage during special enrollment periods.
Public perception of the pharmaceutical industry is low, and is not getting any better with constant reports of drug price increases. However, Allergan is looking to deflect harsh criticism with a new promise to limit price hikes on brand-name drugs, reported STAT. Allergan price hikes will be limited to single-digit percentage increases and occur no more than once a year, the CEO wrote in a blog post. He also said the that the company would avoid major price hikes as products get close to losing their patent protection.
For the third time the Senate voted to block the $1.1 billion funding bill to fight the Zika virus. The Hill reported that Democrats nearly unanimously voted to block the bill because of language targeting funding for Planned Parenthood. Mitch McConnell, R-Kentucky, and Paul Ryan, R-Wisconsin, both vow to get a funding deal out the door by the end of September and some Republicans believe that the party will eventually drop language targeting Planned Parenthood in order to get the bill passed. The New York Times has laid out 5 aspects of the Zika funding battle, which has gone on for months.
CMS will institute a process to screen some people who apply for health insurance coverage on HealthCare.gov during special enrollment periods. According to CNBC, the new process would apply to customers buying health plans in the 38 states on HealthCare.gov. The program is the latest effort by the government to appease unhappy insurers who have complained some customers are signing up for coverage as they get sick and then dropping it. A separate confirmation process implemented earlier this year has already reduced ineligible sign-ups by 15%.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More